A molecule in lizard saliva may make it easier to find certain tumors in the pancreas.

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech’s willingness to significantly increase its upfront bet on BNT327 reflects a belief the candidate could set a new ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

Objective responses included: 2 PRs among 3 MSI-H patients with both responders having pancreatic ductal adenocarcinoma. One patient with MSI-H PDAC was initially misclassified as MSI-H small bowel ...

The gut microbiome's impact on pancreatic cancer highlights potential for early screening and fecal microbiota ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for trea ...

Despite progress in cancer treatments, pancreatic cancer remains a formidable foe, with the NHS conceding that it "can be difficult to treat". Timely detection is crucial; however, pancreatic ...

"Moderna and MSD begin trial of mRNA-4157 and Keytruda combination for lung cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...